Financhill
Sell
15

SCLX Quote, Financials, Valuation and Earnings

Last price:
$0.45
Seasonality move :
47.63%
Day range:
$0.43 - $0.45
52-week range:
$0.43 - $2.63
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.01x
P/B ratio:
--
Volume:
976K
Avg. volume:
1.9M
1-year change:
-65.64%
Market cap:
$58.8M
Revenue:
$46.7M
EPS (TTM):
-$1.43

Analysts' Opinion

  • Consensus Rating
    Scilex Holding has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $9.08, Scilex Holding has an estimated upside of 1933.43% from its current price of $0.45.
  • Price Target Downside
    According to analysts, the lowest downside price target is $6.25 representing -1299.15% downside risk from its current price of $0.45.

Fair Value

  • According to the consensus of 1 analyst, Scilex Holding has 1933.43% upside to fair value with a price target of $9.08 per share.

SCLX vs. S&P 500

  • Over the past 5 trading days, Scilex Holding has underperformed the S&P 500 by -10.2% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • Scilex Holding does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Scilex Holding has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Scilex Holding reported revenues of $16.4M.

Earnings Growth

  • Scilex Holding has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Scilex Holding reported earnings per share of -$0.31.
Enterprise value:
156.4M
EV / Invested capital:
--
Price / LTM sales:
1.01x
EV / EBIT:
--
EV / Revenue:
3.08x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
13.49x
Price / Operating cash flow:
4.43x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$34.7M
Return On Assets:
-117.93%
Net Income Margin (TTM):
-233.88%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-95.44%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-06-30 2023-06-30 2024-06-30 2023-06-30 2024-06-30
Income Statement
Revenue -- $46.5M $50.8M $12.6M $16.4M
Gross Profit -- $30.6M $34.7M $8.4M $12M
Operating Income -- -$78.6M -$99.1M -$22.8M -$15.6M
EBITDA -- -$41.5M -$112.6M -$25.6M -$36M
Diluted EPS -- -$0.38 -$1.43 -$0.19 -$0.31
Period Ending 2020-06-30 2021-06-30 2022-06-30 2023-06-30 2024-06-30
Balance Sheet
Current Assets -- -- -- $69.2M $50.4M
Total Assets -- -- -- $126.5M $104.5M
Current Liabilities -- -- -- $103.6M $255.5M
Total Liabilities -- -- -- $116M $319.2M
Total Equity -- -- -- $10.4M -$214.7M
Total Debt -- -- -- $34.4M $104.4M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-06-30 2023-06-30 2024-06-30 2023-06-30 2024-06-30
Cash Flow Statement
Cash Flow Operations -- -$19.4M $12.2M -$13.5M $2.3M
Cash From Investing -- -$15K -$622K -$8K -$150K
Cash From Financing -- $47.7M -$37.1M $43.5M $4.7M
Free Cash Flow -- -$19.4M $11.6M -$13.5M $2.2M
SCLX
Sector
Market Cap
$58.8M
$44.6M
Price % of 52-Week High
16.99%
45.71%
Dividend Yield
0%
0%
Shareholder Yield
-22.79%
-0.68%
1-Year Price Total Return
-65.64%
-29.09%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $0.49
200-day SMA
Sell
Level $1.14
Bollinger Bands (100)
Sell
Level 0.66 - 1.18
Chaikin Money Flow
Sell
Level -85M
20-day SMA
Sell
Level $0.57
Relative Strength Index (RSI14)
Sell
Level 30.91
ADX Line
Sell
Level 13.78
Williams %R
Buy
Level -94.4518
50-day SMA
Sell
Level $0.74
MACD (12, 26)
Sell
Level -0.08
25-day Aroon Oscillator
Sell
Level -56
On Balance Volume
Sell
Level -28.3M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-11.9676)
Sell
CA Score (Annual)
Level (-11.343)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (21.398)
Buy
Piotroski F Score (Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Stock Forecast FAQ

In the current month, SCLX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SCLX average analyst price target in the past 3 months is $9.08.

  • Where Will Scilex Holding Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Scilex Holding share price will rise to $9.08 per share over the next 12 months.

  • What Do Analysts Say About Scilex Holding?

    Analysts are divided on their view about Scilex Holding share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Scilex Holding is a Sell and believe this share price will drop from its current level to $6.25.

  • What Is Scilex Holding's Price Target?

    The price target for Scilex Holding over the next 1-year time period is forecast to be $9.08 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is SCLX A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Scilex Holding is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of SCLX?

    You can purchase shares of Scilex Holding via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Scilex Holding shares.

  • What Is The Scilex Holding Share Price Today?

    Scilex Holding was last trading at $0.45 per share. This represents the most recent stock quote for Scilex Holding. Yesterday, Scilex Holding closed at $0.45 per share.

  • How To Buy Scilex Holding Stock Online?

    In order to purchase Scilex Holding stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock